ChemoCentryx (CCXI) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
ChemoCentryx Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 6, 2015 4:05 PM EDT- Completed enrollment in the European Vasculitis Phase II CLEAR trial of C5aR inhibitor CCX168; top line data expected by year-end 2015 -
- North American Vasculitis Phase II CLASSIC trial of CCX168 reaches halfway mark in target patient enrollment -
- Initiated Phase II proof-of-concept trial in atypical hemolytic uremic syndrome with CCX168 -
- Pancreatic cancer proof-of-concept trial with CCX872 progressing -
- Conference Call Today at 5:00 p.m. Eastern... More
